Informing the pharmaceutical drug development, manufacturing and commercialization industry.
Cary, NC – May 17, 2016 – A new report titled Biosimilars Manufacturing: Key Considerations and Expected Outsourcing Practices (3rd edition), from Industry Standard Research (ISR), indicates that the majority of companies with a large molecule offering plan to enter or are already involved in the biosimilar market, including companies with no internal manufacturing capabilities. This news supports the projected biosimilar boom, and will ensure a role for contract manufacturers in the biosimilar market as well.
“We saw a considerable shift from last year’s data where 54% of respondents mentioned their company had no plans to sell biosimilars; this year just 36% of respondents reported the same,” explained Kate Hammeke, Director of Market Research at ISR. “A smaller percentage of respondents are currently selling biosimilars, but this change shows that many organizations have reconsidered their position. This reconsideration may have been influenced by the US FDA having approved a biosimilar in the past year.”
In addition to findings on increased interest in selling biosimilars, the report includes key statistics on large molecule manufacturing, drivers for engaging CMOs for biosimilar manufacturing, bioprocessing equipment preferences, and desired geographies for outsourced biosimilar manufacturing to take place. The report also explores perceived challenges specific to manufacturing a follow-on biologic aside from keeping costs under control. Contract manufacturers can get a read on sponsors’ comfort level with outsourcing a biosimilar manufacturing project to their organization.
CMOs included in the report are: AbbVie Contract Manufacturing, Aeras CMO, Althea, Avid Bioservices, Boehringer Ingelheim Bioexcellence, Catalent, Celltrion, CMC Biologics, Cobra Biologics, Cook Pharmica, Cytovance Biologics, Dalton Pharma Services, FujiFilm Diosynth Biotechnologies, GSK Contract Manufacturing, Hetero, IDT Biologika, KBI Biopharma, Kemwell, Lonza, Novasep, Paragon, Patheon, Pfizer CentreSource, Piramal Pharma Solutions, Rentschler, Richter-Helm, SAFC, Samsung BioLogics, Sandoz, Sanofi CEPiA, Therapure Biopharma, and Wuxi AppTec.
This report provides insights into the biosimilar market and where decision-makers at sponsor organizations think it is heading. These data will enable readers to understand and assess perceived challenges to biosimilar manufacturing to make an informed decision on whether to enter the market.
For more information on ISR’s “Bioprocessing Manufacturing: Key Considerations and Expected Outsourcing Practices (3rd edition)” report, please visit ISR’s report page at http://isrreports.wpengine.com/reports/biosimilars-manufacturing-key-considerations-expected-outsourcing-practices-3rd-edition/
About Industry Standard Research
Industry Standard Research is the premier, full service market research provider to the pharma and pharma services industries. With over a decade of experience, ISR delivers an unmatched level of domain expertise. For more information about ISR’s off-the-shelf intelligence and custom research offerings, please visit the company’s website at www.ISRreports.com, email info@ISRreports.com or follow ISR on Twitter @ISRreports.